Clinical trial
A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection
NCT00704184 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 25, 2008
- Completion date
- April 14, 2010
- Enrollment
- 95 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.